Filing Details

Accession Number:
0001209191-19-025791
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-04-24 18:07:46
Reporting Period:
2019-04-22
Accepted Time:
2019-04-24 18:07:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1595893 Turning Point Therapeutics Inc. TPTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1282930 L Carl Gordon C/O Turning Point Therapeutics, Inc.
10628 Science Center Drive, Ste. 225
San Diego CA 92121
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-04-22 1,120,730 $0.00 1,120,730 No 4 C Indirect By OrbiMed Private Investments VI, LP
Common Stock Acquisiton 2019-04-22 546,820 $0.00 1,667,550 No 4 C Indirect By OrbiMed Private Investments VI, LP
Common Stock Acquisiton 2019-04-22 360,000 $18.00 2,027,550 No 4 P Indirect By OrbiMed Private Investments VI, LP
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect By OrbiMed Private Investments VI, LP
No 4 C Indirect By OrbiMed Private Investments VI, LP
No 4 P Indirect By OrbiMed Private Investments VI, LP
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2019-04-22 15,000 $0.00 15,000 $27.06
Common Stock Series C Preferred Stock Disposition 2019-04-22 4,314,809 $0.00 1,120,730 $0.00
Common Stock Series D Preferred Stock Disposition 2019-04-22 2,105,259 $0.00 546,820 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
15,000 2029-04-21 No 4 A Direct
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date.
  2. OrbiMed Capital GP VI LLC (GP VI) is the general partner of OrbiMed Private Investments VI, LP. (OPI VI). OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a member of OrbiMed Advisors. OrbiMed Advisors exercise investment and voting power through a management committee comprised of the Reporting Person, Sven H. Borho and Jonathan T. Silverstein. Each of GP VI, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the shares held by OPI VI, except to the extent of its or his pecuniary interest therein if any.
  3. The shares were purchased at the Issuer's initial public offering.
  4. The option will become fully vested on the date of the Issuer's 2020 annual meeting of stockholders.